** Medical device maker Haemonetics's shares HAE.N rise 4% to $69.79

** BofA Global Research ups to "neutral" from "underperform" and raises PO from $58 to $75, 11.4% above last close

** BofA sees setup as less risky since HAE's "prudent" forecast does not depend on rebound in vascular‑closure device Vascade, and also left upside in plasma volume

** Notes HAE lowered Vascade recovery expectations, meaning a sharp rebound isn't needed just to meet guidance

** Sees upside in plasma volume growth, which returned to high single digits in the US and double digits in Europe last qtr

** Including session's move, HAE stock down ~10% YTD

(Reporting by Padmanabhan Ananthan)

((Padmanabhan.Ananthan@thomsonreuters.com))